GlassScriptPhysician profile
Daniel S Menees
NPI 1043262405
$135,591.33
in general payments reported to CMS, 2019-2025
20 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,477 · 2020: $2,671 · 2021: $13K · 2022: $14K · 2023: $58K · 2024: $16K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Consulting Fee: $28K · Travel and Lodging: $20K · Food and Beverage: $18K · Long Term Medical Supply Or Device Loan: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,378.13 |
| Consulting Fee | $28,450.00 |
| Travel and Lodging | $20,450.28 |
| Food and Beverage | $18,069.91 |
| Long Term Medical Supply Or Device Loan | $281.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $80,730.80 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Apollotm |
| Boston Scientific Corporation | $28,523.27 | 2019-2025 | General - Balloons, Avvigo Guidance System, General - Vascular Access |
| Edwards Lifesciences Corporation | $10,088.66 | 2020-2025 | Pascal, Sapien 3 Ultra Resilia |
| Abbott Laboratories | $6,711.12 | 2019-2025 | Mitraclip, Portico, Triclip |
| Medtronic Vascular, INC. | $4,140.34 | 2019-2020 | |
| Philips North America LLC | $1,807.24 | 2023-2024 | (Bq9) Coronary Ivus, (P84) Igt Devices Systems, (P77) Azurion 7 M20 |
| Siemens Medical Solutions USA, INC. | $1,117.83 | 2021-2022 | |
| Heartflow, INC. | $550.00 | 2025 | |
| Asahi Intecc USA, INC. | $385.40 | 2023-2024 | Asahi Ptca Guide Wire, Peripheral Vascular |
| Teleflex LLC | $376.39 | 2023-2025 | Turnpike, Guideliner, Manta |
| Asahi Intecc Co., LTD. | $265.13 | 2024 | Peripheral Vascular |
| Shockwave Medical, INC | $260.87 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $191.25 | 2024-2025 | Impella |
| Biotronik INC. | $152.08 | 2022-2025 | |
| Cardiovascular Systems INC. | $99.29 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acist Medical Systems, INC. | $85.59 | 2025 | |
| Kestra Medical Technology Services, INC. | $80.34 | 2025 | Assure Wcd |
| Ekos Corporation | $17.22 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.51 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Menees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.